top of page

AmMax Partnering

Partnering is a critical part of AmMax’s integrated growth strategy. It was initially built on the partnership with Amgen via the licensing of a potent monoclonal antibody targeting CSF1R. Following the partnership with Evopoint Biosciences, AmMax brought in a next generation ADC with the potential to address multiple solid tumors.

We are actively seeking to license in or acquire additional oncology assets. We are also looking to out-license a number of non-core assets. Please contact for further information.


LifeMax licensed the worldwide rights to AMG820, now designated AMB-05X, which is in clinical development for tenosynovial giant cell tumor. The same molecule is also being developed for idiopathic pulmonary fibrosis, polycystic kidney diseases and an undisclosed indication.

Evopoint Logo_English.png

AmMax entered into an exclusive option to license agreement with Evopoint for the ex-China right to develop and commercialize a next generation ADC, now designated AMB-101, for the potential treatment of a broad range of solid tumors.

bottom of page